Search Results - "Sant, P"

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials by Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D

“…Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene…”
Get full text

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial by Trigo, José, Subbiah, Vivek, Besse, Benjamin, Moreno, Victor, López, Rafael, Sala, María Angeles, Peters, Solange, Ponce, Santiago, Fernández, Cristian, Alfaro, Vicente, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Zaman, Khalil, Boni, Valentina, Arrondeau, Jennifer, Martínez, Maite, Delord, Jean-Pierre, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Wannesson, Luciano, Valdivia, Javier, Rubio, María Jesús, Anton, Antonio, Sarantopoulos, John, Chawla, Sant P, Mosquera-Martinez, Joaquín, D'Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M, Sands, Jacob, Paz-Ares, Luis

“…Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of…”
Get full text

Giant Cell Tumor of Bone: An Update by Basu Mallick, Atrayee, Chawla, Sant P.

“…Purpose of Review To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was…”
Get full text

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial by Heinrich, Michael C, Jones, Robin L, von Mehren, Margaret, Schöffski, Patrick, Serrano, César, Kang, Yoon-Koo, Cassier, Philippe A, Mir, Olivier, Eskens, Ferry, Tap, William D, Rutkowski, Piotr, Chawla, Sant P, Trent, Jonathan, Tugnait, Meera, Evans, Erica K, Lauz, Tamieka, Zhou, Teresa, Roche, Maria, Wolf, Beni B, Bauer, Sebastian, George, Suzanne

“…Targeting of KIT and PDGFRA with imatinib revolutionised treatment in gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated…”
Get full text

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors by Demetri, George D, De Braud, Filippo, Drilon, Alexander, Siena, Salvatore, Patel, Manish R, Cho, Byoung Chul, Liu, Stephen V, Ahn, Myung-Ju, Chiu, Chao-Hua, Lin, Jessica J, Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Thomas, Fakih, Marwan, Chawla, Sant P, Dziadziuszko, Rafal, Seto, Takashi, Heinzmann, Sebastian, Pitcher, Bethany, Chen, David, Wilson, Timothy R, Rolfo, Christian

“…Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable…”
Get full text

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial by Jones, Robin L., Serrano, César, von Mehren, Margaret, George, Suzanne, Heinrich, Michael C., Kang, Yoon-Koo, Schöffski, Patrick, Cassier, Philippe A., Mir, Olivier, Chawla, Sant P., Eskens, Ferry A.L.M., Rutkowski, Piotr, Tap, William D., Zhou, Teresa, Roche, Maria, Bauer, Sebastian

“…PDGFRA D842V mutations occur in 5–10% of gastrointestinal stromal tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive…”
Get full text

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial by Tap, William D, Papai, Zsuzsanna, Van Tine, Brian A, Attia, Steven, Ganjoo, Kristen N, Jones, Robin L, Schuetze, Scott, Reed, Damon, Chawla, Sant P, Riedel, Richard F, Krarup-Hansen, Anders, Toulmonde, Maud, Ray-Coquard, Isabelle, Hohenberger, Peter, Grignani, Giovanni, Cranmer, Lee D, Okuno, Scott, Agulnik, Mark, Read, William, Ryan, Christopher W, Alcindor, Thierry, del Muro, Xavier F Garcia, Budd, G Thomas, Tawbi, Hussein, Pearce, Tillman, Kroll, Stew, Reinke, Denise K, Schöffski, Patrick

“…Evofosfamide is a hypoxia-activated prodrug of bromo-isophosphoramide mustard. We aimed to assess the benefit of adding evofosfamide to doxorubicin as…”
Get full text

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy by DEMETRI, George D, CHAWLA, Sant P, REICHARDT, Peter, BOMPAS, Emmanuelle, ALCINDOR, Thierry, RUSHING, Daniel, YANG SONG, LEE, Ruey-Min, EBBINGHAUS, Scot, EID, Joseph E, LOEWY, John W, HALUSKA, Frank G, RAY-COQUARD, Isabelle, DODION, Pierre F, BLAY, Jean-Yves, LE CESNE, Axel, STADDON, Arthur P, MILHEM, Mohammed M, PENEL, Nicolas, RIEDEL, Richard F, BUI-NGUYEN, Binh, CRANMER, Lee D

“…Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of…”
Get full text

Block copolymer micelles: preparation, characterization and application in drug delivery by Gaucher, Geneviève, Dufresne, Marie-Hélène, Sant, Vinayak P., Kang, Ning, Maysinger, Dusica, Leroux, Jean-Christophe

“…Block copolymer micelles are generally formed by the self-assembly of either amphiphilic or oppositely charged copolymers in aqueous medium. The hydrophilic…”
Get full text

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model by Higuchi, Takashi, Miyake, Kentaro, Oshiro, Hiromichi, Sugisawa, Norihiko, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Chawla, Sant P., Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.

“…Recurrent osteosarcoma is a chemotherapy-resistant disease. Individualized precision therapy is needed for this disease. Toward this goal, we have developed…”
Get full text

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study by PAPPO, Alberto S, PATEL, Shreyaskumar R, GANJOO, Kristen N, SCHUETZE, Scott M, JUERGENS, Heribert, LEAHY, Michael G, GEOERGER, Birgit, BENJAMIN, Robert S, HELMAN, Lee J, BAKER, Laurence H, CROWLEY, John, REINKE, Denise K, KUENKELE, Klaus-Peter, CHAWLA, Sant P, TONER, Guy C, MAKI, Robert G, MEYERS, Paul A, CHUGH, Rashmi

“…The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a…”
Get full text

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives by Gordon, Erlinda M., Sankhala, K. Kumar, Chawla, Neal, Chawla, Sant P.

“…Trabectedin (ET743, Yondelis ® , manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the…”
Get full text

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules by DEMETRI, George D, CHAWLA, Sant P, LEBEDINSKY, Claudia, ELSAYED, Yusri A, IZQUIERDO, Miguel A, GOMEZ, Javier, PARK, Youn C, LE CESNE, Axel, VON MEHREN, Margaret, RITCH, Paul, BAKER, Laurence H, BLAY, Jean Y, HANDE, Kenneth R, KEOHAN, Mary L, SAMUELS, Brian L, SCHUETZE, Scott

“…To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic…”
Get full text

Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model by Yamamoto, Jun, Miyake, Kentaro, Han, Qinghong, Tan, Yuying, Inubushi, Sachiko, Sugisawa, Norihiko, Higuchi, Takashi, Tashiro, Yoshihiko, Nishino, Hiroto, Homma, Yuki, Matsuyama, Ryusei, Chawla, Sant P., Bouvet, Michael, Singh, Shree Ram, Endo, Itaru, Hoffman, Robert M.

“…Methionine addiction is a fundamental and general hallmark of cancer. Gene expression analysis showed that methionine restriction (MR) of methionine-addicted…”
Get full text

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas by CHAWLA, Sant P, STADDON, Arthur P, RIVERA, Victor M, CLACKSON, Tim, LOEWY, John W, HALUSKA, Frank G, DEMETRI, George D, BAKER, Laurence H, SCHUETZE, Scott M, TOLCHER, Anthony W, D'AMATO, Gina Z, BLAY, Jean-Yves, MITA, Monica M, SANKHALA, Kamalesh K, BERK, Lori

“…Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence…”
Get full text

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma by Riedel, Richard F, Chua, Victoria, Moradkhani, Ania, Krkyan, Natalie, Ahari, Amir, Osada, Atsushi, Chawla, Sant P

“…NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. The nanoparticle…”
Get full text

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) by Chawla, Sant P, Tellez, Walter Andree, Chomoyan, Hripsime, Valencia, Chrysler, Ahari, Amir, Omelchenko, Nadezhda, Makrievski, Stefan, Brigham, Don A, Chua-Alcala, Victoria, Quon, Doris, Moradkhani, Ania, Gordon, Erlinda M

“…Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin…”
Get full text

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial by van der Graaf, Winette TA, Prof, Blay, Jean-Yves, Prof, Chawla, Sant P, MD, Kim, Dong-Wan, MD, Bui-Nguyen, Binh, MD, Casali, Paolo G, MD, Schöffski, Patrick, Prof, Aglietta, Massimo, MD, Staddon, Arthur P, MD, Beppu, Yasuo, MD, Le Cesne, Axel, MD, Gelderblom, Hans, Prof, Judson, Ian R, Prof, Araki, Nobuhito, MD, Ouali, Monia, MSc, Marreaud, Sandrine, MD, Hodge, Rachel, MSc, Dewji, Mohammed R, MSc, Coens, Corneel, MSc, Demetri, George D, MD, Fletcher, Christopher D, Prof, Dei Tos, Angelo Paolo, MD, Hohenberger, Peter, Prof

“…Summary Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue…”
Get full text

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma by Chawla, Sant P, Cranmer, Lee D, Van Tine, Brian A, Reed, Damon R, Okuno, Scott H, Butrynski, James E, Adkins, Douglas R, Hendifar, Andrew E, Kroll, Stew, Ganjoo, Kristen N

“…TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study…”
Get full text

A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma by Chawla, Sant P, Goel, Sanjay, Chow, Warren, Braiteh, Fadi, Singh, Arun S, Olson, Juneko E Grilley, Osada, Atsushi, Bobe, Iulian, Riedel, Richard F

“…NC-6300 is a novel nanoparticle formulation of epirubicin that has a pH-sensitive linker conjugated to epirubicin. It exhibits selective tumor accumulation…”
Get full text